Barclays analyst Andrew Mok raised the firm’s price target on CVS Health (CVS) to $101 from $93 and keeps an Overweight rating on the shares post the Q1 report. CVS delivered a strong start to the year across all segments, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health reports Q1 adjusted EPS $2.57, consensus $2.21
- CVS Health raises FY26 adjusted EPS view to $7.30-$7.50 from $7.00-$7.20
- CVS Health raises FY26 revenue view to ‘at least’ $405B from ‘at least’ $400B
- CVS Health says ‘encouraged’ by Q1 performance
- CVS Health says confident in adequacy of reserves